Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Cigna Group's change in receivables for the fiscal year that ended in Dec. 2025 was €-3,954 Mil. It means The Cigna Group's Accounts Receivable
increased by €3,954 Mil
from Dec. 2024 to Dec. 2025 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
The Cigna Group's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 35.55.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. The Cigna Group's liquidation value for the
three
months ended in Mar. 2026 was €-69,333 Mil.
The Cigna Group (WBO:CIGN) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
The Cigna Group's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cigna Group Change In Receivables Related Terms
The Cigna Group Change In Receivables Historical Data
* Premium members only.
The historical data trend for The Cigna Group's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-263 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of €-263 Mil mean?
The Cigna Group (WBO:CIGN) has a Change In Receivables of €-263 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for The Cigna Group and its competitors.
Is The Cigna Group's Change In Receivables too high?
The Cigna Group's current Change In Receivables is €-263 Mil. Overall, The Cigna Group has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cigna Group's Change In Receivables compare to ELV and HUM?
The Cigna Group's Change In Receivables of €-263 Mil can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Plans company?
A good Change In Receivables depends on the Healthcare Plans industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for The Cigna Group and its competitors. The Cigna Group's current Change In Receivables is €-263 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cigna Group stock overvalued right now?
Based on GuruFocus' analysis, The Cigna Group (WBO:CIGN) is currently considered Modestly Undervalued. The stock's GF Value™ is €369.89, compared to a current price of €266.40 — trading 28% below its estimated fair value. The current Change In Receivables is €-263 Mil. The Cigna Group's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For The Cigna Group (WBO:CIGN), the current Change In Receivables is €-263 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cigna Group (WBO:CIGN) Overvalued in 2026?
Based on GuruFocus' analysis, The Cigna Group stock appears to be undervalued.
The current stock price of €266.40 is trading 28% below its estimated GF Value™ of €369.89.
GuruFocus considers The Cigna Group to be Modestly Undervalued.
Key valuation signals for WBO:CIGN:
Change In Receivables: €-263 Mil
GF Value™: €369.89 vs. price of €266.40 (28% below fair value)
No single metric tells the full story. See the WBO:CIGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
66GF Score
Get the complete analysis for WBO:CIGN
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:CIGN has been successfully added to your 
